Trevi Therapeutics, Inc. (TRVI) - Q3 2025 Filing Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 30, 2025. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing Haduvio (oral nalbuphine ER), an investigational therapy for chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). The company has no approved products and has not generated any product revenue.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9 Months 2025 | 9 Months 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(11,802) | $(13,242) | $(34,443) | $(36,496) |
| Operating Expenses | $13,916 | $14,087 | $39,108 | $39,281 |
| Interest Income, Net | $2,101 | $826 | $4,633 | $2,759 |
| Cash & Cash Equivalents | $56,869 | $16,052 | $56,869 | $16,052 |
| Marketable Securities | $138,058 | $73,525 | $138,058 | $73,525 |
| Total Liquidity | $194,927 | $89,577 | $194,927 | $89,577 |
| Accumulated Deficit | $(321,488) | $(275,630) | $(321,488) | $(275,630) |
Note: The filing text does not provide a specific "profit margin" as the company has no revenue. Operating expenses were flat year-over-year for the quarter but increased slightly for the nine-month period due to higher G&A costs.
Material Changes vs. Prior Period
- Liquidity Increase: Total cash, cash equivalents, and marketable securities increased from $89.6 million at September 30, 2024, to $194.9 million at September 30, 2025. This was driven by a June 2025 underwritten public offering that raised approximately $115.1 million in gross proceeds.
- Expense Management: Research and Development (R&D) expenses decreased by $1.1 million in Q3 2025 compared to Q3 2024, primarily due to reduced clinical development costs for the Phase 2a RIVER and Phase 2b CORAL trials which were actively enrolling in the prior year. General and Administrative (G&A) expenses increased by $0.97 million due to higher professional fees (SOX 404 compliance) and personnel costs.
- Interest Income: Net interest income more than doubled in Q3 2025 ($2.1M vs $0.8M) due to higher invested cash balances and prevailing interest rates.
- Share Count: Outstanding common shares increased to approximately 128.2 million as of September 30, 2025, from 75.5 million in the prior year period, reflecting recent equity issuances.
Guidance, Outlook, and Risks
- Clinical Progress:
- IPF Program: Announced positive topline results from the Phase 2b CORAL trial in June 2025, showing statistically significant reductions in cough frequency across all dose groups. The company plans to request an End-of-Phase 2 meeting with the FDA in Q4 2025 and initiate Phase 3 trials in H1 2026.
- RCC Program: Announced positive topline data from the Phase 2a RIVER trial in March 2025. A Phase 2b trial is planned for initiation in H1 2026.
- Non-IPF ILD: Planning a clinical trial for chronic cough in patients with non-IPF ILD.
- TIDAL Study: Ongoing Phase 1 study to evaluate respiratory function and safety in IPF patients; data expected in Q4 2025.
- Capital Outlook: Management believes current resources ($194.9 million) will fund operations into 2028, covering planned Phase 3 trials for IPF, trials for non-IPF ILD and RCC, and NDA supportive studies. However, additional capital will be required to complete development through regulatory approval and commercialization.
- Key Risks:
- Single Product Dependence: The company relies entirely on the success of Haduvio.
- Regulatory Uncertainty: Haduvio is an opioid (nalbuphine); approval may carry class warnings for respiratory depression. The company is pursuing a Section 505(b)(2) pathway, which carries specific regulatory risks.
- Third-Party Reliance: Reliance on a single supplier (Mallinckrodt) for the active pharmaceutical ingredient (nalbuphine hydrochloride).
- Financing Needs: Failure to raise additional capital could force delays or abandonment of development programs.
Investor Verification Checklist
- Cash Runway: Verify the specific burn rate assumptions used to project funding into 2028, particularly given the high costs of Phase 3 trials.
- Phase 3 Design: Confirm the FDA's feedback on the Phase 3 trial design for IPF following the anticipated Q4 2025 End-of-Phase 2 meeting.
- Supply Chain: Assess the status of any efforts to qualify alternative suppliers for nalbuphine hydrochloride to mitigate single-source risk.
- Warrant Dilution: Review the terms and exercise prices of outstanding warrants (approx. 19.1 million shares underlying warrants as of Sept 30, 2025) and their potential impact on future dilution.
- SOX Compliance: Monitor the impact of Sarbanes-Oxley Section 404(b) compliance costs on future G&A expenses.